Inovio Pharmaceuticals (Inovio Pharmaceuticals) GF Value : $5.98 (As of Apr. 25, 2024)

View and export this data going back to 1998. Start your Free Trial

What is Inovio Pharmaceuticals GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-04-25), Inovio Pharmaceuticals's share price is $9.96. Inovio Pharmaceuticals's GF Value is $5.98. Therefore, Inovio Pharmaceuticals's Price-to-GF-Value for today is 1.67.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Inovio Pharmaceuticals is Significantly Overvalued.

Inovio Pharmaceuticals (NAS:INO) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Inovio Pharmaceuticals's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	9.96	/	5.98
	=	1.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inovio Pharmaceuticals GF Value Related Terms

Thank you for viewing the detailed overview of Inovio Pharmaceuticals's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Inovio Pharmaceuticals (Inovio Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inovio Pharmaceuticals Inc (NAS:INO) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

INO:Mexico GBMB:Germany GBMB:Germany

Address

660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462

Website

https://www.inovio.com

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Executives

Lota S. Zoth	director	334 CR 692, BUFFALO GAP TX 79508
David B. Weiner	director	717 BEACOM LANE, MERION STATION PA 19066-1603
Simon X Benito	director	967 LAWRENCE AVE, WESTFIELD NJ 07090
Michael John Sumner	officer: Chief Medical Officer	660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Laurent Humeau	officer: Chief Scientific Officer	C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Jacqueline Elizabeth Shea	officer: Chief Operating Officer	C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Peter Kies	officer: CFO
Roger D Dansey	director	21823 30TH DRIVE SE, BOTHELL WA 98021
Jong Joseph Kim	director, officer: Chief Executive Officer	660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Jay Shepard	director	15977 GRANDVIEW AVENUE, MONTE SERENO CA 95030
Ann Calby Miller	director	C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Wendy L Yarno	director
Morton Collins	director
George Bickerstaff	director	C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Niranjan Sardesai	officer: Chief Operating Officer	VGX PHARMACEUTICALS, INC., 450 SENTRY PARKWAY, BLUE BELL PA 19422